GlassScriptPrepare for your visit
Sucha Kim
Pulmonary Disease · Los Angeles, CA · NPI 1205916145
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$4,090.30
in general payments reported to CMS, 2019-2025 · $678 in 2025
The $678 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Who reported paying
General payments only, top 6 by amount.
- Glaxosmithkline, LLC. $1,269.95
- Boehringer Ingelheim Pharmaceuticals, INC. $806.09
- Insmed, INC. $193.81
- Inari Medical, INC. $189.75
- Cvrx, INC. $169.05
- Astrazeneca Pharmaceuticals LP $153.79
Drugs and devices associated with these payments
Nucala Trelegy Ellipta Ofev Flowtriever Catheter, S Ct Thrombectomy System Kit Barostim Neo System Arikayce Prolastin-C Liquid Arexvy Spiriva Respimat Tyvaso Acthar
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Sucha Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/100181/sucha-kim